Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Orexin in the anxiety spectrum: association of a HCRTR1 polymorphism with panic disorder/agoraphobia, CBT treatment response and fear-related intermediate phenotypes
Michael G. Gottschalk, Jan Richter, Christiane Ziegler, et al.
Translational Psychiatry (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 71
Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders
Ying Han, Kai Yuan, Yongbo Zheng, et al.
Neuroscience Bulletin (2019) Vol. 36, Iss. 4, pp. 432-448
Open Access | Times Cited: 77
Chronic insomnia, REM sleep instability and emotional dysregulation: A pathway to anxiety and depression?
Dieter Riemann, Raphael J. Dressle, Fee Benz, et al.
Journal of Sleep Research (2024)
Open Access | Times Cited: 9
Recent perspectives on orexin/hypocretin promotion of addiction-related behaviors
F. Woodward Hopf
Neuropharmacology (2020) Vol. 168, pp. 108013-108013
Open Access | Times Cited: 50
Neurobiology of the Orexin System and Its Potential Role in the Regulation of Hedonic Tone
Martin A. Katzman, Matthew P. Katzman
Brain Sciences (2022) Vol. 12, Iss. 2, pp. 150-150
Open Access | Times Cited: 30
Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions
Harry Fagan, David S. Baldwin
Expert Review of Neurotherapeutics (2023) Vol. 23, Iss. 6, pp. 535-548
Open Access | Times Cited: 21
ENIGMA‐anxietyworking group: Rationale for and organization oflarge‐scaleneuroimaging studies of anxiety disorders
Janna Marie Bas‐Hoogendam, Nynke A. Groenewold, Moji Aghajani, et al.
Human Brain Mapping (2020) Vol. 43, Iss. 1, pp. 83-112
Open Access | Times Cited: 44
Three-dimensional Interrogation of Cell Types and Instinctive Behavior in the Periaqueductal Gray
Eric Vaughn, Stephen W. Eichhorn, Won Jung, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 25
Clinical usefulness of dual orexin receptor antagonism beyond insomnia: Neurological and psychiatric comorbidities
Matteo Carpi, Laura Palagini, Mariana Fernandes, et al.
Neuropharmacology (2023) Vol. 245, pp. 109815-109815
Open Access | Times Cited: 15
Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders
Alessandro Bonifazi, Fabio Del Bello, Gianfabio Giorgioni, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 5, pp. 1607-1667
Closed Access | Times Cited: 13
Acute orexin antagonism selectively modulates anticipatory anxiety in humans: implications for addiction and anxiety
Stephanie M. Gorka, Kia J. Khorrami, Charles A. Manzler, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 20
Orexin A in adolescents with anxiety disorders
Ömer Faruk Akça, Necati Uzun, İbrahim Kılınç
International Journal of Psychiatry in Clinical Practice (2020) Vol. 24, Iss. 2, pp. 127-134
Closed Access | Times Cited: 28
Polymorphisms and association of GRM1, GNAQ and HCRTR1 genes with seasonal reproduction and litter size in three sheep breeds
Mengting Zhu, Hongmei Zhang, Hua Yang, et al.
Reproduction in Domestic Animals (2022) Vol. 57, Iss. 5, pp. 532-540
Closed Access | Times Cited: 16
First‐in‐human study with ACT‐539313, a novel selective orexin‐1 receptor antagonist
Priska Kaufmann, Marion Anliker‐Ort, Georg Golor, et al.
British Journal of Clinical Pharmacology (2020) Vol. 86, Iss. 7, pp. 1377-1386
Open Access | Times Cited: 23
Fifteen years of NESDA Neuroimaging: An overview of results related to clinical profile and bio-social risk factors of major depressive disorder and common anxiety disorders
Marie‐José van Tol, Nic J.A. van der Wee, Dick J. Veltman
Journal of Affective Disorders (2021) Vol. 289, pp. 31-45
Open Access | Times Cited: 17
The role of basolateral amygdala orexin 1 receptors on the modulation of pain and psychosocial deficits in nitroglycerin-induced migraine model in adult male rats
Khadijeh Askari-Zahabi, Mehdi Abbasnejad, Razieh Kooshki, et al.
The Korean journal of pain (2021) Vol. 35, Iss. 1, pp. 22-32
Open Access | Times Cited: 14
Combination therapy with neuropeptides for the treatment of anxiety disorder
Priti Ramakant Gupta, Kedar S. Prabhavalkar
Neuropeptides (2021) Vol. 86, pp. 102127-102127
Closed Access | Times Cited: 13
The involvement of orexin 1 and cannabinoid 1 receptors within the ventrolateral periaqueductal gray matter in the modulation of migraine-induced anxiety and social behavior deficits of rats
Ali Mohammad Pourrahimi, Mehdi Abbasnejad, Maryam Raoof, et al.
Peptides (2021) Vol. 146, pp. 170651-170651
Closed Access | Times Cited: 12
Hypocretin (Orexin) Replacement Therapies
Erica Seigneur, Luı́s de Lecea
Medicine in Drug Discovery (2020) Vol. 8, pp. 100070-100070
Open Access | Times Cited: 12
Experimental Drugs for Panic Disorder: An Updated Systematic Review
Daniela Caldirola, Alessandra Alciati, Francesco Cuniberti, et al.
Journal of Experimental Pharmacology (2021) Vol. Volume 13, pp. 441-459
Open Access | Times Cited: 10
The role of the orexin system in the neurobiology of anxiety disorders: Potential for a novel treatment target
Harry Fagan, Nathan T. M. Huneke, Katharina Domschke, et al.
Neuroscience Applied (2023) Vol. 3, pp. 103922-103922
Open Access | Times Cited: 3
Possible Benefits of Considering Glutamate with Melatonin or Orexin or Oxytocin as a Combination Approach in the Treatment of Anxiety
Ruchita Ravindra Dhangar, Pravin Popatrao Kale, Pramod Kadu, et al.
Current Pharmacology Reports (2019) Vol. 6, Iss. 1, pp. 1-7
Closed Access | Times Cited: 8
CO2 reactivity as a biomarker of exposure-based therapy non-response: study protocol
Jasper A. J. Smits, Marie‐H. Monfils, Michael W. Otto, et al.
BMC Psychiatry (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 5
Association of orexin/hypocretin receptor gene (HCRTR1) with reward sensitivity, and interaction with gender
Aleksander Pulver, Evelyn Kiive, Margus Kanarik, et al.
Brain Research (2020) Vol. 1746, pp. 147013-147013
Open Access | Times Cited: 7
Estrogens, age, and, neonatal stress: panic disorders and novel views on the contribution of non-medullary structures to respiratory control and CO2 responses
Richard Kinkead, Danuzia A. Marques, Stéphanie Fournier, et al.
Frontiers in Physiology (2023) Vol. 14
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top